Biotech News

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease

Allogene Therapeutics (ALLO)Allogene TherapeuticsClinical readout

Favorable Early Safety Profile in 18 Patients with No DLTs, IEC-HS, ICANS, GvHD or Grade ≥3 CRS Initial Efficacy Analysis Focused on Skin-Predominant Systemic Sclerosis (SSc/Scleroderma), a Severe Autoimmune Disease with Significant Unmet Need Clinical Activity Observed in SSc Across All

Related news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

Stock data

Close
0.67 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States